Nabumetone Tillomed Laboratories (Nabumetone)

Nabumetone acts on inflammatory pathways to reduce pain and swelling in several musculoskeletal disorders.

• Rheumatoid arthritis: reduces joint pain, swelling and stiffness, improving functional ability.
• Osteoarthritis: alleviates chronic joint discomfort and enhances mobility.
• Ankylosing spondylitis: diminishes spinal inflammation and associated pain.
• General musculoskeletal pain: provides analgesic relief for acute and chronic pain states.

• Nabumetone is a pro‑drug that is metabolised to its active form, which selectively inhibits cyclooxygenase (COX) enzymes, primarily COX‑2. By blocking COX‑mediated conversion of arachidonic acid to prostaglandins, it reduces the synthesis of inflammatory mediators, thereby decreasing pain, swelling, and fever associated with inflammatory conditions.

Nabumetone may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Gastrointestinal discomfort, such as dyspepsia or nausea.
• Headache or dizziness.
• Mild skin rash or pruritus.
• Elevated liver enzymes detected on routine testing.
• Transient increase in blood pressure.

Serious or Rare Side Effects

• Gastrointestinal ulceration or bleeding, which can be life‑threatening.
• Cardiovascular events, including myocardial infarction or stroke.
• Severe skin reactions such as Stevens‑Johnson syndrome.
• Hepatic failure or severe liver injury.
• Acute renal impairment or failure.

Before prescribing nabumetone, clinicians should consider several safety factors.

• Renal function: monitor in patients with existing kidney disease or dehydration.
• Gastrointestinal risk: avoid in individuals with a history of peptic ulcer or GI bleeding.
• Cardiovascular health: use cautiously in patients with hypertension or established heart disease.
• Hepatic status: assess liver enzymes periodically, especially in long‑term therapy.
• Concomitant medications: review for potential drug interactions that may increase toxicity.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Nabumetone can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): increased risk of serious bleeding.
• Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity.
• Systemic corticosteroids: heightened chance of ulceration and bleeding.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: possible reduction in renal function.
• Diuretics: may exacerbate renal impairment.
• Selective serotonin reuptake inhibitors (SSRIs): increased bleeding tendency.